SAGE Electrochromics, Inc. Company Profile

21:35 EDT 20th March 2018 | BioPortfolio

SAGE Electrochromics is the world’s leading manufacturer of advanced dynamic glass that can be tinted or cleared to optimize daylight and improve the human experience in buildings. SageGlass controls the sunlight and heat that enter a building, significantly reducing energy consumption while improving people’s comfort and well-being. SageGlass can reduce a building’s cooling load by 20% and HVAC requirements up to 30%. It is a smarter, more elegant solution than conventional sun controls such as mechanical window shades, blinds and louvers. The company was founded in 1989 and is headquartered near Minneapolis-St. Paul, Minn., in the heart of “the Silicon Valley of the window industry.” SAGE is a wholly owned subsidiary of Saint-Gobain of Paris, France, the world’s largest building materials company.

News Articles [151 Associated News Articles listed on BioPortfolio]

Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test

Sage Therapeutics disclosed another clinical trial victory this morning, sending shares of the Cambridge, MA, company to new highs. An experimental Sage drug for major depressive disorder (MDD), a psy...

Sage Therapeutics Reports Positive Top-Line Results from Phase II Placebo-Controlled Trial of SAGE-217 in MDD

NewsSAGE-217 was generally well-tolerated with no serious or severe adverse events.Contributed Author:&

Sage's major depressive disorder drug given FDA breakthrough status

Sage Therapeutics' SAGE-217, which is being assessed in a late-stage study for the treatment of patients with major depressiv -More- 

Active-Investors: Blog Exposure - Sage Therapeutics Declared Positive Results from Phase-1/2 Clinical Trial of SAGE-217 in Treatment of Insomnia

LONDON, UK / ACCESSWIRE / February 02, 2018 / has just released a free research report on Sage Therapeutics, Inc. (NASDAQ: SAGE). If you want access to this report all you need...

Sage stock soars with positive Phase 2 in major depression

Hope increases for patients with major depressive disorder as Sage Therapeutics' SAGE-217 meets its primary endpoint, with rapid and durable effects over six weeks of treatment.

Sage Therapeutics' SAGE-217 shows positive effect in phase 1/2 insomnia trial

Sage Therapeutics’ sleep disorder drug SAGE-217 has yielded positive results from a phase 1/2 trial in healthy adult volunteers using a 5-hour phase advance model of insomnia using polysomnography.

#Biopharma Stock News: Sage Therapeutics (NASDAQ: $SAGE) Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression

CAMBRIDGE, Mass. - November 9, 2017 ( Newswire) Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central n...

STAT Plus: Wall Street loves Sage’s experimental antidepressant. Will patients?

Although Sage Therapeutics' (SAGE) experimental antidepressant has been great for its stock price — it soared 70 percent on Thursday after the company announced mostly positive results from a Phase&...

PubMed Articles [52 Associated PubMed Articles listed on BioPortfolio]

The Chemotaxonomy of Common Sage (Salvia officinalis) Based on the Volatile Constituents.

Background: Common sage (Salvia officinalis) is a popular culinary and medicinal herb. A literature survey has revealed that sage oils can vary widely in their chemical compositions. The purpose of th...

Essential oils from Origanum vulgare and Salvia officinalis exhibit antibacterial and anti-biofilm activities against Streptococcus pyogenes.

In the present study, essential oils (EOs) extracted from oregano, sage, cloves, and ginger were evaluated for the phytochemical profile, antibacterial, and anti-biofilm activities against Streptococc...

Probability of lek collapse is lower inside sage-grouse Core Areas: Effectiveness of conservation policy for a landscape species.

Greater sage-grouse (Centrocercus urophasianus) occupy sagebrush (Artemisia spp.) habitats in 11 western states and 2 Canadian provinces. In September 2015, the U.S. Fish and Wildlife Service announce...

The SAGE Model of Social Psychological Research.

We propose a SAGE model for social psychological research. Encapsulated in our acronym is a proposal to have a synthetic approach to social psychological research, in which qualitative methods are aug...

Effect of zinc gluconate, sage oil on inflammatory patterns and hyperglycemia in zinc deficient diabetic rats.

The relationship between zinc homeostasis and pancreatic function had been established. In this study we aimed firstly to configure the inflammatory pattern and hyperglycemia in zinc deficient diabeti...

Clinical Trials [24 Associated Clinical Trials listed on BioPortfolio]

Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients

The purpose of this study is to determine the effectiveness of the herb sage in improving the mental function of individuals with Alzheimer's disease. Study hypothesis: The administration...

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

This study will assess the pharmacodynamic effects of SAGE-217 in approximately 42 healthy adult subjects using an insomnia model.

A Study to Evaluate SAGE-217 in Patients With Parkinson's Disease of Moderate Severity

This study will assess the safety, tolerability, pharmacokinetics and efficacy of SAGE-217 in up to 30 subjects with Parkinson's Disease of Moderate Severity.

A Study to Evaluate SAGE-217 in Subjects With Essential Tremor

This study is a two-part, multicenter, Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in up to 80 adult subjects with essential tremor.

A Study to Evaluate SAGE-547 in Patients With Moderate Postpartum Depression

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in up to 36 adult female subje...

Companies [28 Associated Companies listed on BioPortfolio]

SAGE Electrochromics, Inc.

SAGE Electrochromics is the world’s leading manufacturer of advanced dynamic glass that can be tinted or cleared to optimize daylight and improve the human experience in buil...

SAGE Therapeutics, Inc.

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous syste...

Sage Science, Inc.

Sage Science develops game-changing instrument products for life science research and diagnostic laboratories. Sage Science is privately held. For more information visit www.sages...

Sage Science

Sage Science develops game-changing instrument products for life science research and diagnostic laboratories. Sage Science is privately held. For more information visit www.sages...

Sage Software Healthcare, LLC

For nearly 30 years, physicians have trusted Sage to deliver solutions that enable them to optimize their patients' experience while enhancing their bottom line. Sage Software Healthcare, LLC, provide...

More Information about "SAGE Electrochromics, Inc." on BioPortfolio

We have published hundreds of SAGE Electrochromics, Inc. news stories on BioPortfolio along with dozens of SAGE Electrochromics, Inc. Clinical Trials and PubMed Articles about SAGE Electrochromics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SAGE Electrochromics, Inc. Companies in our database. You can also find out about relevant SAGE Electrochromics, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Corporate Database Quicklinks

Searches Linking to this Company Record